Managing Anemia and Splenomegaly in Myelofibrosis

These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.

The Best of CAR T at the 2024 Tandem Meetings Webinar Series, which aired on June 27, 2024, aimed to provide a comprehensive overview of the latest advancements and research in CAR T cell therapy.